1/24/2022 7:11:22 AM
Karyopharm Receives Orphan Drug Designation From FDA For Eltanexor For Treatment Of Myelodysplastic Syndromes
1/10/2022 7:12:38 AM
Karyopharm Expects Net Product Revenues Of XPOVIO To Be About $29.7 Mln For Q4
12/21/2021 8:57:10 AM
Karyopharm And Menarini To Commercialize NEXPOVIO In Europe And Other Key Global Territories
12/21/2021 7:32:55 AM
Karyopharm And Menarini Group To Commercialize NEXPOVIO In Europe And Other Key Global Territories
12/11/2021 12:08:52 PM
Karyopharm Announces Presentation Of Updated Phase 2 Selinexor Data In Patients With Myelofibrosis
12/6/2021 4:09:34 PM
Karyophar Appoints Peter Honig To Its Board Of Directors
12/6/2021 7:07:45 AM
Karyopharm :First Patient Dosed In Phase 2 Study Evaluating Selinexor Versus Physician's Choice In Myelofibrosis
12/2/2021 7:14:01 AM
Karyopharm Completes Patient Recruitment In Phase 3 SIENDO Study Of Selinexor In Patients With Endometrial Cancer
11/3/2021 7:16:01 AM
Karyopharm Q3 Loss/shr Narrows To $0.69 From $0.73 Last Year
10/21/2021 8:12:47 AM
Karyopharm Reports Dosing Of First Patient In Phase 2 Study Oral Eltanexor In HMA Refractory Myelodysplastic Syndrome